Loading
किडनी रोग में एरिथ्रोपोइटिन (EPO) घटने से होने वाली खून की कमी — हीमोग्लोबिन घटता है। इलाज: EPO थेरेपी, आयरन, और सूजन नियंत्रण। लक्ष्य Hb 10-12 g/dL (KDIGO)।
Renal anemia develops due to insufficient erythropoietin (EPO) production by peritubular fibroblasts in the kidneys as CKD progresses. Other contributing factors include functional iron deficiency (hepcidin-mediated iron blockade), inflammation (cytokine-mediated suppression), reduced red cell lifespan due to uremia, and blood loss (especially in HD patients from dialyzer retention and laboratory draws). Management follows KDOQI Anemia Guidelines (2012): iron repletion before ESA initiation (ferritin >200 ng/mL, TSAT >20%); ESA initiation when Hb <10 g/dL; target Hb range 10-11.5 g/dL (avoid >13 g/dL per TREAT trial safety data). Hyporesponsiveness to ESA requires investigation for iron deficiency, inflammation, hyperparathyroidism, malignancy, and medication non-adherence.
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.